Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,262 Mln
P/E Ratio
--
P/B Ratio
2
Industry P/E
--
Debt to Equity
0.04
ROE
-0.88 %
ROCE
-82.18 %
Div. Yield
0 %
Book Value
6.18
EPS
-3.11
CFO
$769.13 Mln
EBITDA
$1,448.50 Mln
Net Profit
$-1,808.54 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Dyne Therapeutics Inc (DYN)
| -53.06 | -10.73 | -19.39 | -55.72 | 9.30 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Dyne Therapeutics Inc (DYN)
| 76.32 | 14.75 | -2.52 | -43.38 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of... muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Read more
Chief Operating Officer
Ms. Susanna Gatti High M.B.A.
Chief Operating Officer
Ms. Susanna Gatti High M.B.A.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Dyne Therapeutics Inc (DYN) stood at $ 691 Mln as on 31-Dec-24
The share price of Dyne Therapeutics Inc (DYN) is $11.06 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Dyne Therapeutics Inc (DYN) has given a return of 9.3% in the last 3 years.
Dyne Therapeutics Inc (DYN) has a market capitalisation of $ 1,262 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Dyne Therapeutics Inc (DYN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Dyne Therapeutics Inc (DYN) and enter the required number of quantities and click on buy to purchase the shares of Dyne Therapeutics Inc (DYN).
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
The CEO & director of Ms. Susanna Gatti High M.B.A.. is Dyne Therapeutics Inc (DYN), and CFO & Sr. VP is Ms. Susanna Gatti High M.B.A..
There is no promoter pledging in Dyne Therapeutics Inc (DYN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Dyne Therapeutics Inc (DYN) | Ratios |
|---|---|
|
Return on equity(%)
|
-88.03
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Dyne Therapeutics Inc (DYN) was $0 Mln.
$-0.05
(
